Brief: Beam Therapeutics BEAM-302 Was Well Tolerated At All Dose Levels
10/03/2025 10:11
March 10 (Reuters) - Beam Therapeutics Inc BEAM.O: BEAM THERAPEUTICS: BEAM-302 WAS WELL TOLERATED AT ALL DOSE LEVELS BEAM THERAPEUTICS: SINGLE DOSE OF BEAM-302 LED TO DURABLE, DOSE-DEPENDENT INCREASES IN TOTAL AND FUNCTIONAL ALPHA-1 ANTITRYPSIN Source text: ID:nGNX1XfmpR Further company coverage: BEAM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beam Therapeutics
See all newsBeam Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Beam Therapeutics Q1 net loss narrows beating analyst estimates
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta